Calreticulin mutations and long-term survival in essential thrombocythemia

Leukemia

Volumn 28, Issue 12, 2014, Pages 2300-2303

  Tefferi, A ^a   Wassie, E A ^a   Lasho, T L ^a   Finke, C ^a   Belachew, A A ^a   Ketterling, R P ^a   Hanson, C A ^a   Pardanani, A ^a   Gangat, N ^a   Wolanskyj, A P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; CALRETICULIN; CHLORAMBUCIL; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; MYELOPROLIFERATIVE LEUKEMIA VIRUS PROTEIN; PHOSPHORUS 32; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SEX DIFFERENCE; SEX RATIO; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; COMPLICATION; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; THROMBOCYTHEMIA, ESSENTIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 84927094466     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.148     Document Type: Article

References (15)

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
3. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013; 123: 1552-1555.
4. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013; 123: 1544-1551.
5. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
6. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
7. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
8. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28: 1494-1500.
9. Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804-1810.
10. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-276.
11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
12. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
13. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
14. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
15. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al. A prognostic model to predict survival in 867 World Health Organizationdefined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197-1201.